262 related articles for article (PubMed ID: 19035443)
1. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Ashida A; Takata M; Murata H; Kido K; Saida T
Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
[TBL] [Abstract][Full Text] [Related]
2. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences.
Dai B; Cai X; Kong YY; Yang F; Shen XX; Wang LW; Kong JC
Hum Pathol; 2013 Aug; 44(8):1472-8. PubMed ID: 23528861
[TBL] [Abstract][Full Text] [Related]
3. Somatic activation of KIT in distinct subtypes of melanoma.
Curtin JA; Busam K; Pinkel D; Bastian BC
J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
[TBL] [Abstract][Full Text] [Related]
4. KIT gene mutations and patterns of protein expression in mucosal and acral melanoma.
Abu-Abed S; Pennell N; Petrella T; Wright F; Seth A; Hanna W
J Cutan Med Surg; 2012; 16(2):135-42. PubMed ID: 22513068
[TBL] [Abstract][Full Text] [Related]
5. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Buchbinder EI; Sosman JA; Lawrence DP; McDermott DF; Ramaiya NH; Van den Abbeele AD; Linette GP; Giobbie-Hurder A; Hodi FS
Cancer; 2015 Nov; 121(22):4007-15. PubMed ID: 26264378
[TBL] [Abstract][Full Text] [Related]
7. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.
Torres-Cabala CA; Wang WL; Trent J; Yang D; Chen S; Galbincea J; Kim KB; Woodman S; Davies M; Plaza JA; Nash JW; Prieto VG; Lazar AJ; Ivan D
Mod Pathol; 2009 Nov; 22(11):1446-56. PubMed ID: 19718013
[TBL] [Abstract][Full Text] [Related]
8. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
[TBL] [Abstract][Full Text] [Related]
9. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential.
Huang S; Luca M; Gutman M; McConkey DJ; Langley KE; Lyman SD; Bar-Eli M
Oncogene; 1996 Dec; 13(11):2339-47. PubMed ID: 8957075
[TBL] [Abstract][Full Text] [Related]
10. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.
Hofmann UB; Kauczok-Vetter CS; Houben R; Becker JC
Clin Cancer Res; 2009 Jan; 15(1):324-9. PubMed ID: 19118061
[TBL] [Abstract][Full Text] [Related]
12. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
[TBL] [Abstract][Full Text] [Related]
13. KIT amplification and gene mutations in acral/mucosal melanoma in Korea.
Yun J; Lee J; Jang J; Lee EJ; Jang KT; Kim JH; Kim KM
APMIS; 2011 Jun; 119(6):330-5. PubMed ID: 21569090
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib therapy for melanoma patients with KIT mutations.
Minor DR; Kashani-Sabet M; Garrido M; O'Day SJ; Hamid O; Bastian BC
Clin Cancer Res; 2012 Mar; 18(5):1457-63. PubMed ID: 22261812
[TBL] [Abstract][Full Text] [Related]
15. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
16. KIT pathway alterations in mucosal melanomas of the vulva and other sites.
Omholt K; Grafström E; Kanter-Lewensohn L; Hansson J; Ragnarsson-Olding BK
Clin Cancer Res; 2011 Jun; 17(12):3933-42. PubMed ID: 21680547
[TBL] [Abstract][Full Text] [Related]
17. Large-scale analysis of KIT aberrations in Chinese patients with melanoma.
Kong Y; Si L; Zhu Y; Xu X; Corless CL; Flaherty KT; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lu A; Guo J
Clin Cancer Res; 2011 Apr; 17(7):1684-91. PubMed ID: 21325067
[TBL] [Abstract][Full Text] [Related]
18. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
[TBL] [Abstract][Full Text] [Related]
19. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
[TBL] [Abstract][Full Text] [Related]
20. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]